How do I interpret a sterility result with no sampling plan attached?

My setup is a refrigerator with a logger and a small work area I wipe down, nothing more.

I have read the primary source rather than the summary, which has left me with more questions.

I understand the headline. I do not understand the footnotes, and the footnotes look important.

How should I read this, and where are the traps?

The honest answer is that nobody in this market is selling a sterile product and that claims to the contrary should increase your scepticism.

Terminal sterilisation — moist heat, dry heat or irradiation — is not applicable to most lyophilised peptides, which is why aseptic processing is the pharmaceutical route and why it is expensive.

Put another way, lyophilised powder has a water activity too low to support microbial growth, so a contaminated powder stays at the contamination level it arrived with until water is added. Adding water starts the clock.

Nothing here is medical advice.

A sterility claim without a test report is a marketing claim.

Aseptic technique reduces what you add; it does nothing about what arrived.

A pharmacopoeial sterility test is destructive and statistical: a defined number of units from a batch are incubated in two media for fourteen days. Passing establishes a probability, not a certainty, and it can only be done by the manufacturer on the batch.

Bacteriostatic water inhibits growth and does not kill. It buys an in-use period against multiplication; it does not sterilise the preparation or the powder.

Aseptic processing rather than terminal sterilisation is standard for heat-labile biologics, and the associated environmental controls are the reason for the cost difference.

Bacteriostatic water inhibits growth. It does not sterilise anything.

The relevant point is that a lyophilised powder is a hostile environment for growth and a poor argument for sterility.

The practical mitigations are: minimise entries, refrigerate after reconstitution, discard on any change in appearance, and never store a preservative-free reconstituted vial.

Put another way, injection-site infection is the realistic risk and it is uncommon, which is a statement about base rates rather than about safety.

Minimise entries, refrigerate, discard on any change in appearance.

The underlying point is that this is the question where the honest answer is unwelcome and unavoidable.

Filtering into a non-sterile container with a non-sterile technique produces a filtered non-sterile preparation. The container and the environment are part of the system.

The caveat is the whole answer: research-use material is not approved for human use in any jurisdiction, and this discussion is about handling, not about permission.

Assume non-sterile. Everything else in this tag follows from that.

Answering this needs the distinction between sterile, aseptically handled and low-bioburden, which are three different claims.

A 0.22 micrometre filter removes bacteria and fungi. It does not remove viruses, endotoxin or any dissolved chemical impurity, and it costs you some peptide adsorbed onto the membrane.

Absence of a problem so far is not evidence of sterility; it is evidence of a low base rate.

Filtration removes organisms, not endotoxin, and it costs you peptide.